SINOMAB BIOSCIENCE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.9 HKD | +2.15% |
|
+10.47% | +13.10% |
| Mar. 25 | SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 07 | SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
SinoMab BioScience Ltd is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE). The Companyâs product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is developing drugs for the treatment of RA, systemic lupus erythematosus (SLE), asthma, pemphigus, sjogrenâs syndrome (SS) and other immunological diseases.
Sector
Pharmaceuticals
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.10% | 259M | |
| -5.32% | 84.57B | |
| +3.95% | 39.93B | |
| -26.37% | 27.93B | |
| +52.09% | 24.21B | |
| -6.59% | 17.17B | |
| -32.37% | 13.93B | |
| -10.45% | 12.3B | |
| -15.88% | 11.84B | |
| -2.85% | 7.91B |
- Stock Market
- Equities
- 3681 Stock
- News SinoMab BioScience Limited
- SinoMab BioScience : China Authorizes SinoMab's Lupus Drug as Treatment for Another Autoimmune Disease
